Real-world test of adebrelimab combo for tough cancers
NCT ID NCT07173244
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular medical practice rather than a strict experiment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adebrelimab (a cancer immunotherapy drug)
What this could lead to
If successful, this could provide real-world evidence on how well adebrelimab combinations work and their safety in advanced solid tumors.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It is early-stage and may not lead to new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••